Natco Pharma Ltd.

Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 September 2026, providing investors with the latest insights into the company’s performance and outlook.

Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s share price has declined by 1.92% to ₹866.45, reflecting growing investor caution amid mixed technical signals and a downgrade in its Mojo Grade from Hold to Sell.

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite a modest day gain of 1.16%, the company’s technical parameters reveal a complex picture, prompting a downgrade in its Mojo Grade from Hold to Sell as of 4 August 2026.

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals. Recent technical parameter changes have prompted a downgrade in its Mojo Grade from Hold to Sell, underscoring growing investor caution amid subdued price action and mixed indicator readings.

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s share price has declined sharply by 5.23% on 17 Aug 2026, reflecting growing investor caution amid mixed technical signals and a downgrade in its Mojo Grade from Hold to Sell.

Natco Pharma Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 4 August 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock's current position as of 16 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. Despite a recent downgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical parameters suggest a nuanced outlook for investors navigating this evolving landscape.

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite a modest year-to-date return outperforming the Sensex, recent technical parameters suggest caution for investors as the stock’s momentum deteriorates.

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 4 August 2026. This shift reflects deteriorating financial performance, subdued valuation appeal, and a weakening technical outlook, signalling caution for investors amid challenging market conditions.

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish to a mildly bearish stance. This change is reflected in key technical indicators such as MACD, RSI, moving averages, and Bollinger Bands, signalling a cautious outlook for investors amid recent price declines and mixed trend signals.

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential deterioration in the stock’s trend and raises concerns about long-term weakness amid mixed fundamental and technical metrics.

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently exhibited a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is underscored by a combination of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, suggesting cautious optimism among traders and investors as the stock navigates current market conditions.